Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.

ClinicalTrials.gov IDNCT02610439

PhaseNot Applicable

Enrollment575

SponsorNational Cancer Institute (NCI)

AgeNo minimum reported

SexALL

I'm interested View official listing

Conditions studied

Breast Carcinoma, Neuropathy

About this study

Interventions

Other: Laboratory Biomarker Analysis — Correlative studies

Primary outcomes

Identification of rare coding variants of large effect that predict the risk of peripheral neuropathy (Baseline)

Eligibility information

Inclusion Criteria: * European American patients with DNA available and designated case or control * African American patients with DNA available and designated case or control status * Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel

Study locations

Eastern Cooperative Oncology Group, Boston, Massachusetts 02215 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.